Cargando…
High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma
Malignant pleural mesothelioma (MPM) has a rich stromal component containing mesenchymal fibroblasts. However, the properties and interplay of MPM tumor cells and their surrounding stromal fibroblasts are poorly characterized. Our objective was to spatially profile known mesenchymal markers in both...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363931/ https://www.ncbi.nlm.nih.gov/pubmed/33955203 http://dx.doi.org/10.1002/cjp2.218 |
_version_ | 1783738440267857920 |
---|---|
author | Ollila, Hely Paajanen, Juuso Wolff, Henrik Ilonen, Ilkka Sutinen, Eva Välimäki, Katja Östman, Arne Anttila, Sisko Kettunen, Eeva Räsänen, Jari Kallioniemi, Olli Myllärniemi, Marjukka Mäyränpää, Mikko I Pellinen, Teijo |
author_facet | Ollila, Hely Paajanen, Juuso Wolff, Henrik Ilonen, Ilkka Sutinen, Eva Välimäki, Katja Östman, Arne Anttila, Sisko Kettunen, Eeva Räsänen, Jari Kallioniemi, Olli Myllärniemi, Marjukka Mäyränpää, Mikko I Pellinen, Teijo |
author_sort | Ollila, Hely |
collection | PubMed |
description | Malignant pleural mesothelioma (MPM) has a rich stromal component containing mesenchymal fibroblasts. However, the properties and interplay of MPM tumor cells and their surrounding stromal fibroblasts are poorly characterized. Our objective was to spatially profile known mesenchymal markers in both tumor cells and associated fibroblasts and correlate their expression with patient survival. The primary study cohort consisted of 74 MPM patients, including 16 patients who survived at least 60 months. We analyzed location‐specific tissue expression of seven fibroblast markers in clinical samples using multiplexed fluorescence immunohistochemistry (mfIHC) and digital image analysis. Effect on survival was assessed using Cox regression analyses. The outcome measurement was all‐cause mortality. Univariate analysis revealed that high expression of secreted protein acidic and cysteine rich (SPARC) and fibroblast activation protein in stromal cells was associated with shorter survival. Importantly, high expression of platelet‐derived growth factor receptor beta (PDGFRB) in tumor cells, but not in stromal cells, was associated with shorter survival (hazard ratio [HR] = 1.02, p < 0.001). A multivariable survival analysis adjusted for clinical parameters and stromal mfIHC markers revealed that tumor cell PDGFRB and stromal SPARC remained independently associated with survival (HR = 1.01, 95% confidence interval [CI] = 1.00–1.03 and HR = 1.05, 95% CI = 1.00–1.11, respectively). The prognostic effect of PDGFRB was validated with an artificial intelligence‐based analysis method and further externally validated in another cohort of 117 MPM patients. In external validation, high tumor cell PDGFRB expression associated with shorter survival, especially in the epithelioid subtype. Our findings suggest PDGFRB and SPARC as potential markers for risk stratification and as targets for therapy. |
format | Online Article Text |
id | pubmed-8363931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83639312021-08-23 High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma Ollila, Hely Paajanen, Juuso Wolff, Henrik Ilonen, Ilkka Sutinen, Eva Välimäki, Katja Östman, Arne Anttila, Sisko Kettunen, Eeva Räsänen, Jari Kallioniemi, Olli Myllärniemi, Marjukka Mäyränpää, Mikko I Pellinen, Teijo J Pathol Clin Res Original Articles Malignant pleural mesothelioma (MPM) has a rich stromal component containing mesenchymal fibroblasts. However, the properties and interplay of MPM tumor cells and their surrounding stromal fibroblasts are poorly characterized. Our objective was to spatially profile known mesenchymal markers in both tumor cells and associated fibroblasts and correlate their expression with patient survival. The primary study cohort consisted of 74 MPM patients, including 16 patients who survived at least 60 months. We analyzed location‐specific tissue expression of seven fibroblast markers in clinical samples using multiplexed fluorescence immunohistochemistry (mfIHC) and digital image analysis. Effect on survival was assessed using Cox regression analyses. The outcome measurement was all‐cause mortality. Univariate analysis revealed that high expression of secreted protein acidic and cysteine rich (SPARC) and fibroblast activation protein in stromal cells was associated with shorter survival. Importantly, high expression of platelet‐derived growth factor receptor beta (PDGFRB) in tumor cells, but not in stromal cells, was associated with shorter survival (hazard ratio [HR] = 1.02, p < 0.001). A multivariable survival analysis adjusted for clinical parameters and stromal mfIHC markers revealed that tumor cell PDGFRB and stromal SPARC remained independently associated with survival (HR = 1.01, 95% confidence interval [CI] = 1.00–1.03 and HR = 1.05, 95% CI = 1.00–1.11, respectively). The prognostic effect of PDGFRB was validated with an artificial intelligence‐based analysis method and further externally validated in another cohort of 117 MPM patients. In external validation, high tumor cell PDGFRB expression associated with shorter survival, especially in the epithelioid subtype. Our findings suggest PDGFRB and SPARC as potential markers for risk stratification and as targets for therapy. John Wiley & Sons, Inc. 2021-05-06 /pmc/articles/PMC8363931/ /pubmed/33955203 http://dx.doi.org/10.1002/cjp2.218 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ollila, Hely Paajanen, Juuso Wolff, Henrik Ilonen, Ilkka Sutinen, Eva Välimäki, Katja Östman, Arne Anttila, Sisko Kettunen, Eeva Räsänen, Jari Kallioniemi, Olli Myllärniemi, Marjukka Mäyränpää, Mikko I Pellinen, Teijo High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title | High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title_full | High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title_fullStr | High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title_full_unstemmed | High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title_short | High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
title_sort | high tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363931/ https://www.ncbi.nlm.nih.gov/pubmed/33955203 http://dx.doi.org/10.1002/cjp2.218 |
work_keys_str_mv | AT ollilahely hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT paajanenjuuso hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT wolffhenrik hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT ilonenilkka hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT sutineneva hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT valimakikatja hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT ostmanarne hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT anttilasisko hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT kettuneneeva hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT rasanenjari hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT kallioniemiolli hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT myllarniemimarjukka hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT mayranpaamikkoi hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma AT pellinenteijo hightumorcellplateletderivedgrowthfactorreceptorbetaexpressionisassociatedwithshortersurvivalinmalignantpleuralepithelioidmesothelioma |